NO20090788L - Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase - Google Patents
Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinaseInfo
- Publication number
- NO20090788L NO20090788L NO20090788A NO20090788A NO20090788L NO 20090788 L NO20090788 L NO 20090788L NO 20090788 A NO20090788 A NO 20090788A NO 20090788 A NO20090788 A NO 20090788A NO 20090788 L NO20090788 L NO 20090788L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- tyrosine kinase
- ret
- receptor tyrosine
- ret receptor
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 title 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84276606P | 2006-09-07 | 2006-09-07 | |
| PCT/GB2007/003335 WO2008029123A1 (en) | 2006-09-07 | 2007-09-06 | Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090788L true NO20090788L (no) | 2009-03-13 |
Family
ID=38829617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090788A NO20090788L (no) | 2006-09-07 | 2009-02-19 | Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110028498A1 (pt) |
| EP (1) | EP2064340A1 (pt) |
| JP (1) | JP2010502209A (pt) |
| KR (1) | KR20090048644A (pt) |
| CN (1) | CN101512017A (pt) |
| AU (1) | AU2007293280A1 (pt) |
| BR (1) | BRPI0716555A2 (pt) |
| CA (1) | CA2662591A1 (pt) |
| IL (1) | IL197157A0 (pt) |
| MX (1) | MX2009002471A (pt) |
| NO (1) | NO20090788L (pt) |
| WO (1) | WO2008029123A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802384B2 (en) * | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| JP6038128B2 (ja) * | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| CN103930571A (zh) * | 2011-11-17 | 2014-07-16 | 瑞尼克斯有限公司 | 用于选择性分子分析的系统和方法 |
| MX2014013806A (es) * | 2012-05-14 | 2014-11-26 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
| EP3470513B1 (en) * | 2013-03-15 | 2020-05-13 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| JP6130755B2 (ja) * | 2013-08-12 | 2017-05-17 | ルネサスエレクトロニクス株式会社 | 半導体装置およびその製造方法 |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| WO2017134115A1 (en) * | 2016-02-01 | 2017-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for determining responsiveness to vandetanib in a patient suffering from medullary thyroid carcinoma |
| JP7280823B2 (ja) * | 2016-11-30 | 2023-05-24 | エクソサム ダイアグノスティクス,インコーポレイティド | 非小細胞肺癌患者由来のエクソソームrna及び無細胞dnaを使用して血漿中の変異を検出するための方法と組成物 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| CN109439752B (zh) * | 2018-11-16 | 2022-02-15 | 上海派森诺医学检验所有限公司 | 一种鉴别甲状腺髓样癌ret基因突变的特异性引物组合及其试剂盒及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| ITMI20021620A1 (it) * | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
-
2007
- 2007-09-06 AU AU2007293280A patent/AU2007293280A1/en not_active Abandoned
- 2007-09-06 KR KR1020097006399A patent/KR20090048644A/ko not_active Withdrawn
- 2007-09-06 MX MX2009002471A patent/MX2009002471A/es not_active Application Discontinuation
- 2007-09-06 JP JP2009527195A patent/JP2010502209A/ja active Pending
- 2007-09-06 CA CA002662591A patent/CA2662591A1/en not_active Abandoned
- 2007-09-06 EP EP07804140A patent/EP2064340A1/en not_active Withdrawn
- 2007-09-06 US US12/438,306 patent/US20110028498A1/en not_active Abandoned
- 2007-09-06 CN CNA2007800330353A patent/CN101512017A/zh active Pending
- 2007-09-06 BR BRPI0716555-2A2A patent/BRPI0716555A2/pt not_active IP Right Cessation
- 2007-09-06 WO PCT/GB2007/003335 patent/WO2008029123A1/en not_active Ceased
-
2009
- 2009-02-19 IL IL197157A patent/IL197157A0/en unknown
- 2009-02-19 NO NO20090788A patent/NO20090788L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101512017A (zh) | 2009-08-19 |
| EP2064340A1 (en) | 2009-06-03 |
| MX2009002471A (es) | 2009-03-20 |
| IL197157A0 (en) | 2009-11-18 |
| WO2008029123A1 (en) | 2008-03-13 |
| BRPI0716555A2 (pt) | 2013-09-24 |
| AU2007293280A1 (en) | 2008-03-13 |
| JP2010502209A (ja) | 2010-01-28 |
| CA2662591A1 (en) | 2008-03-13 |
| KR20090048644A (ko) | 2009-05-14 |
| US20110028498A1 (en) | 2011-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090788L (no) | Metode for evaluering av pasienter for behandling med medikamenter mot RET-reseptor tyrosinkinase | |
| EA200901550A1 (ru) | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений | |
| NO20056236L (no) | Behandling med anti-VEGF-antistoffer | |
| BRPI0908026B8 (pt) | uso de rifaximina no tratamento de doenças do intestino | |
| WO2009019230A3 (en) | Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease | |
| CY1119513T1 (el) | Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης | |
| NO20070521L (no) | Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40 | |
| WO2012009382A3 (en) | Molecular indicators of bladder cancer prognosis and prediction of treatment response | |
| WO2009133197A3 (en) | Levels of april in serum and use in diagnostic methods | |
| WO2010116003A3 (en) | Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy | |
| WO2017167942A8 (en) | Method for predicting the response of melanoma patients to a medicament | |
| Regensburger et al. | Motor and non-motor fluctuations in Parkinson’s disease: the knowns and unknowns of current therapeutic approaches | |
| WO2006059252A3 (en) | Methods and fluorinated compositions for treating amyloid-related diseases | |
| NO330943B1 (no) | En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav. | |
| WO2009004914A1 (ja) | フッ素およびヒドロキシ基で置換されたアルコキシ基を有するpetプローブ | |
| EP1962674A4 (en) | IMPLANTABLE MEDICINE PRODUCT WITH STATUS REPORT | |
| WO2009016231A3 (en) | Compositions and methods for detecting histamine related disorders | |
| WO2007085958A3 (en) | Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker | |
| WO2006046270A3 (en) | Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof | |
| WO2010148323A3 (en) | Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus-related virus | |
| 두건문 | The risk factors, diagnosis and treatment guideline of erectile dysfunction | |
| ATE529750T1 (de) | Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target | |
| WO2017059276A8 (en) | Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation | |
| Ettala et al. | Erectile dysfunction cannot be used in primary screening of pre-diabetes | |
| Raij et al. | Office and Ambulatory Blood Pressure–Lowering Effects of Combination Valsartan/Hydrochlorothiazide vs Hydrochlorothiazide‐Based Therapy in Obese, Hypertensive Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |